Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
MRK Stock Summary
Top 10 Correlated ETFs
MRK
In the News
Three-Stock Lunch: Tesla, Merck, and RH
Jerry Castellini, Castle Ark Management president and CIO, joins 'Power Lunch' to discuss Castellini's investing take on three stocks: Tesla, Merck, and RH.
Merck shares move higher as lung disorder drug secures ‘squeaky clean' label from FDA
Merck & Co Inc (NYSE:MRK, ETR:6MK) shares traded more than 4% higher after it won US Food and Drug Administration (FDA) approval for its lung disorder drug sotatercept, brand name WINREVAIR. After being granted breakthrough therapy designation by the agency, the drug is now the first FDA-approved activin signalling inhibitor therapy for pulmonary arterial hypertension (PAH), a rare, progressive and life-threatening disease where the blood vessels in an individual's lungs thicken and narrow and cause strain on the heart.
Merck Stock Nabs Record High After FDA Approval
Merck & Co Inc (NYSE:MRK) was last seen up 4.4% to trade at $130.99, after the Food and Drug Administration (FDA) approved its Winrevair treatment for adults with high blood pressure due to constriction of lung arteries.
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Zacks.com users have recently been watching Merck & Co. (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Merck (MRK) Gets FDA Approval for New PAH Drug Winrevair
Merck's (MRK) Winrevair becomes the first novel activin signaling inhibitor approved by the FDA to treat PAH.
Merck shares rise on FDA approval for Winrevair
Merck shares gain 5% to $131.90 in afterhours trading following approval of its new drug for a potentially fatal lung disease.
FDA approves Merck's drug for rare, deadly lung condition
The approval is a win for Merck, which is working to diversify its revenue stream as its blockbuster cancer drug Keytruda nears a loss of market exclusivity.
US FDA approves Merck's blood pressure therapy
The U.S. FDA on Tuesday approved Merck's treatment for adults with high blood pressure due to constriction of lung arteries, adding another potential blockbuster drug to the pharmaceutical giant's portfolio
Merck's $11.5 Billion Bet on Its Next Big Drug Finally Arrives
The newly approved drug, which treats potentially fatal pulmonary arterial hypertension, is estimated to ring up as much as $7.5 billion in yearly sales.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
MRK Financial details
MRK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 18.45 | 18.97 | 19.25 | 23.41 | 23.6 | |
Net income per share | 3.88 | 2.79 | 5.16 | 5.73 | 0.14 | |
Operating cash flow per share | 5.29 | 4.05 | 5.58 | 7.54 | 5.13 | |
Free cash flow per share | 3.93 | 2.2 | 3.82 | 5.81 | 3.6 | |
Cash per share | 4.12 | 3.19 | 3.2 | 5.21 | 2.82 | |
Book value per share | 10.2 | 10.01 | 15.09 | 18.16 | 14.81 | |
Tangible book value per share | -3 | -3.73 | -2.35 | 1.81 | -0.62 | |
Share holders equity per share | 10.2 | 10.01 | 15.09 | 18.16 | 14.81 | |
Interest debt per share | 10.73 | 12.89 | 13.4 | 12.5 | 14.38 | |
Market cap | 220.18B | 197.36B | 193.9B | 280.93B | 276.58B | |
Enterprise value | 236.85B | 221.09B | 218.91B | 298.92B | 305.94B | |
P/E ratio | 22.37 | 27.93 | 14.86 | 19.35 | 757.76 | |
Price to sales ratio | 4.7 | 4.11 | 3.98 | 4.74 | 4.62 | |
POCF ratio | 16.38 | 19.25 | 13.74 | 14.71 | 21.27 | |
PFCF ratio | 22.09 | 35.44 | 20.07 | 19.1 | 30.25 | |
P/B Ratio | 8.5 | 7.8 | 5.08 | 6.11 | 7.36 | |
PTB ratio | 8.5 | 7.8 | 5.08 | 6.11 | 7.36 | |
EV to sales | 5.06 | 4.61 | 4.49 | 5.04 | 5.11 | |
Enterprise value over EBITDA | 18.39 | 24.4 | 15.79 | 16.05 | 44.64 | |
EV to operating cash flow | 17.62 | 21.56 | 15.52 | 15.65 | 23.52 | |
EV to free cash flow | 23.76 | 39.7 | 22.66 | 20.33 | 33.46 | |
Earnings yield | 0.04 | 0.04 | 0.07 | 0.05 | 0 | |
Free cash flow yield | 0.05 | 0.03 | 0.05 | 0.05 | 0.03 | |
Debt to equity | 1.02 | 1.26 | 0.87 | 0.67 | 0.94 | |
Debt to assets | 0.31 | 0.35 | 0.31 | 0.28 | 0.33 | |
Net debt to EBITDA | 1.29 | 2.62 | 1.8 | 0.97 | 4.28 | |
Current ratio | 1.24 | 1.02 | 1.27 | 1.47 | 1.25 | |
Interest coverage | 10.33 | 6.54 | 13.21 | 15.29 | 2.6 | |
Income quality | 1.37 | 1.45 | 1.14 | 1.31 | 35.63 | |
Dividend Yield | 0.03 | 0.03 | 0.03 | 0.02 | 0.03 | |
Payout ratio | 0.58 | 0.88 | 0.51 | 0.48 | 20.4 | |
Sales general and administrative to revenue | 0.19 | 0.18 | 0.16 | 0.13 | 0 | |
Research and developement to revenue | 0.21 | 0.28 | 0.25 | 0.23 | 0.51 | |
Intangibles to total assets | 0.4 | 0.38 | 0.42 | 0.38 | 0.37 | |
Capex to operating cash flow | -0.26 | -0.46 | -0.32 | -0.23 | -0.3 | |
Capex to revenue | -0.07 | -0.1 | -0.09 | -0.07 | -0.06 | |
Capex to depreciation | -0.95 | -1.29 | -1.38 | -1.12 | -1 | |
Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Graham number | 29.83 | 25.08 | 41.85 | 48.41 | 6.92 | |
ROIC | 0.15 | 0.07 | 0.13 | 0.17 | 0.01 | |
Return on tangible assets | 0.19 | 0.12 | 0.21 | 0.21 | 0.01 | |
Graham Net | -15.7 | -19.4 | -19.54 | -15.75 | -19.86 | |
Working capital | 5.26B | 437M | 6.39B | 11.48B | 6.47B | |
Tangible asset value | -7.62B | -9.44B | -5.94B | 4.59B | -1.57B | |
Net current asset value | -30.91B | -38.42B | -37.17B | -27.38B | -36.87B | |
Invested capital | 1.02 | 1.26 | 0.87 | 0.67 | 0.94 | |
Average receivables | 6.92B | 7.31B | 8.54B | 9.34B | 10.26B | |
Average payables | 3.53B | 4.17B | 4.6B | 4.44B | 4.09B | |
Average inventory | 5.71B | 6.14B | 6.13B | 5.93B | 6.13B | |
Days sales outstanding | 52.82 | 59.71 | 69.17 | 58.18 | 67.5 | |
Days payables outstanding | 96.68 | 108.29 | 123.46 | 89.39 | 89.6 | |
Days of inventory on hand | 154.62 | 148.73 | 159.46 | 123.92 | 145.25 | |
Receivables turnover | 6.91 | 6.11 | 5.28 | 6.27 | 5.41 | |
Payables turnover | 3.78 | 3.37 | 2.96 | 4.08 | 4.07 | |
Inventory turnover | 2.36 | 2.45 | 2.29 | 2.95 | 2.51 | |
ROE | 0.38 | 0.28 | 0.34 | 0.32 | 0.01 | |
Capex per share | -1.37 | -1.85 | -1.76 | -1.73 | -1.52 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 5.45 | 5.71 | 5.92 | 6.29 | 5.78 | |
Net income per share | 1.19 | 1.11 | -2.35 | 1.87 | -0.48 | |
Operating cash flow per share | 1.75 | 0.53 | 1.46 | 3.04 | 0.1 | |
Free cash flow per share | 1.29 | 0.13 | 1.08 | 2.69 | -0.29 | |
Cash per share | 5.2 | 4.1 | 2.53 | 3.47 | 2.83 | |
Book value per share | 18.14 | 18.45 | 15.24 | 16.26 | 14.84 | |
Tangible book value per share | 1.81 | 2.3 | -0.83 | 0.36 | -0.62 | |
Share holders equity per share | 18.14 | 18.45 | 15.24 | 16.26 | 14.84 | |
Interest debt per share | 12.19 | 12.21 | 14.65 | 13.87 | 14.07 | |
Market cap | 281.37B | 270.02B | 292.98B | 261.18B | 276.15B | |
Enterprise value | 299.37B | 291.03B | 324.18B | 287.4B | 305.51B | |
P/E ratio | 23.32 | 23.93 | -12.26 | 13.76 | -56.31 | |
Price to sales ratio | 20.34 | 18.64 | 19.49 | 16.36 | 18.88 | |
POCF ratio | 63.51 | 201.66 | 79.1 | 33.85 | 1.12K | |
PFCF ratio | 85.76 | 813.31 | 106.96 | 38.32 | -371.67 | |
P/B Ratio | 6.12 | 5.77 | 7.57 | 6.33 | 7.35 | |
PTB ratio | 6.12 | 5.77 | 7.57 | 6.33 | 7.35 | |
EV to sales | 21.65 | 20.09 | 21.56 | 18.01 | 20.88 | |
Enterprise value over EBITDA | 84.66 | 75.14 | -66.69 | 47.92 | 449.94 | |
EV to operating cash flow | 67.58 | 217.35 | 87.52 | 37.24 | 1.24K | |
EV to free cash flow | 91.24 | 876.58 | 118.36 | 42.17 | -411.18 | |
Earnings yield | 0.01 | 0.01 | -0.02 | 0.02 | 0 | |
Free cash flow yield | 0.01 | 0 | 0.01 | 0.03 | 0 | |
Debt to equity | 0.67 | 0.66 | 0.95 | 0.85 | 0.94 | |
Debt to assets | 0.28 | 0.29 | 0.35 | 0.33 | 0.33 | |
Net debt to EBITDA | 5.09 | 5.42 | -6.42 | 4.37 | 43.24 | |
Current ratio | 1.47 | 1.44 | 1.28 | 1.38 | 1.25 | |
Interest coverage | 11.25 | 11.91 | -17.55 | 18.92 | -0.96 | |
Income quality | 1.47 | 0.47 | -0.62 | 1.63 | -0.2 | |
Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Payout ratio | 0.58 | 0.66 | -0.32 | 0.39 | -1.51 | |
Sales general and administrative to revenue | 0.04 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.27 | 0.3 | 0.89 | 0.21 | 0.6 | |
Intangibles to total assets | 0.38 | 0.38 | 0.39 | 0.38 | 0.37 | |
Capex to operating cash flow | -0.26 | -0.75 | -0.26 | -0.12 | -4.02 | |
Capex to revenue | -0.08 | -0.07 | -0.06 | -0.06 | -0.07 | |
Capex to depreciation | -1.29 | -1.02 | -1.07 | -0.89 | -1.03 | |
Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Graham number | 22.03 | 21.48 | 28.41 | 26.16 | 12.71 | |
ROIC | 0.03 | 0.03 | -0.07 | 0.07 | 0 | |
Return on tangible assets | 0.04 | 0.04 | -0.09 | 0.07 | -0.02 | |
Graham Net | -15.72 | -15.31 | -18.56 | -17.66 | -19.9 | |
Working capital | 11.48B | 10.27B | 6.58B | 8.86B | 6.47B | |
Tangible asset value | 4.59B | 5.84B | -2.12B | 918M | -1.57B | |
Net current asset value | -27.38B | -27.49B | -35.75B | -33.47B | -36.87B | |
Invested capital | 0.67 | 0.66 | 0.95 | 0.85 | 0.94 | |
Average receivables | 9.47B | 10.51B | 11.93B | 11.98B | 11.37B | |
Average payables | 3.82B | 3.97B | 3.56B | 3.48B | 3.72B | |
Average inventory | 5.76B | 5.89B | 5.9B | 6.03B | 6.24B | |
Days sales outstanding | 61.5 | 71.92 | 73.55 | 65.82 | 68.11 | |
Days payables outstanding | 98.88 | 84.36 | 76.98 | 74.06 | 105.68 | |
Days of inventory on hand | 137.08 | 134.4 | 132.63 | 129.41 | 171.32 | |
Receivables turnover | 1.46 | 1.25 | 1.22 | 1.37 | 1.32 | |
Payables turnover | 0.91 | 1.07 | 1.17 | 1.22 | 0.85 | |
Inventory turnover | 0.66 | 0.67 | 0.68 | 0.7 | 0.53 | |
ROE | 0.07 | 0.06 | -0.15 | 0.12 | -0.03 | |
Capex per share | -0.45 | -0.4 | -0.38 | -0.36 | -0.39 |
MRK Frequently Asked Questions
What is Merck & Co., Inc. stock symbol ?
Merck & Co., Inc. is a US stock , located in Kenilworth of Nj and trading under the symbol MRK
Is Merck & Co., Inc. buy or a sell ?
32 stock analysts have 32 predictions with a medium analyst target price of $110.25. The lowest prediction is $76 and the highest is $294
What is MRK stock prediction ?
With a median analyst target price of $140.67, 3 stock analysts have made 3 forecasts in last 90 days. $135 is the lowest and $145 is the greatest projection.
What is Merck & Co., Inc. stock quote today ?
Merck & Co., Inc. stock price is $132.06 today.
Is Merck & Co., Inc. stock public?
Yes, Merck & Co., Inc. is a publicly traded company.